JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina.

PURPOSE OF REVIEW: The aim of this review is to describe knowledge, mainly of the last 15 years, that changed criteria for specific treatment against Trypanosoma cruzi infection.

RECENT FINDINGS: Over the past 15 years, there has been an increase in the use of new methodologies to evaluate the efficacy of antiparasitic treatments. These tools showed that the evaluation period for trypanocidal treatment effectiveness could be shortened. Based on the hypothesis that Chagas' cardiomyopathy may indeed be triggered by persistent parasitic infection, it seems plausible that trypanocidal therapy may delay, reduce or prevent the progression to the disease.

SUMMARY: Based on the present knowledge, we can assume that every patient infected with Trypanosoma cruzi in the acute phase and in the early chronic phase (i.e. children under 16 years old) must be treated, and adults could be treated. In this area, research priorities should target obtaining new drugs to allow shorter treatments with fewer adverse reactions and improving new tools to confirm cure when patients are treated during the Chronic Phase.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app